MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Pliant Therapeutics Inc

Fermé

1.52 3.4

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.46

Max

1.54

Chiffres clés

By Trading Economics

Revenu

13M

-43M

Marge bénéficiaire

-2,190.837

Employés

171

EBITDA

17M

-42M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+79.87% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-13M

91M

Ouverture précédente

-1.88

Clôture précédente

1.52

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Pliant Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 oct. 2025, 20:45 UTC

Résultats

Costco Wholesale Sales Climb in September, Early October

8 oct. 2025, 20:12 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct. 2025, 16:39 UTC

Principaux Mouvements du Marché

Mining Shares Rise as Gold Prices Soar

8 oct. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Finance Acquisition Using Internal Funds

8 oct. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct. 2025, 21:54 UTC

Market Talk
Résultats

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct. 2025, 21:26 UTC

Market Talk
Résultats

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

8 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 oct. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct. 2025, 15:43 UTC

Acquisitions, Fusions, Rachats

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparaison

Variation de prix

Pliant Therapeutics Inc prévision

Objectif de Prix

By TipRanks

79.87% hausse

Prévisions sur 12 Mois

Moyen 2.68 USD  79.87%

Haut 4 USD

Bas 1.7 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

6 ratings

1

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

1.43 / 1.6Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat